If you cannot read this message, click here.
     DDNews Top 5 Cancer Stories
       MARCH 2015
From our March 2015 issue:
MMRF and Inflection collaborate on new cancer treatment
By Jeffrey Bouley, DDNews Chief Editor
Current focus is on preclinical testing of innovative dual-mechanism PIM/PI3K inhibitor IBL-202

From our March 2015 issue:
Advancing NSCLC diagnosis and treatment
By Lloyd Dunlap, DDNews Managing Editor
Biocept and Insight Genetics team up to evaluate expression and mutation in ALK therapeutic target

From DDNews Online:
Eisai, Merck enter clinical trial collaboration
By Kelsey Kaustinen, DDNews Senior Editor
The companies will evaluate Merck's pembrolizumab in combination with two of Eisai's oncology compounds in a number of clinical trials

From DDNews Online:
Epizyme secures global rights to EZH2 program
By Kelsey Kaustinen, DDNews Senior Editor
Epizyme will make an upfront payment of $40 million to Eisai for the program rights, as well as up to $70 million in other milestone payments

From DDNews Online:
Bristol-Myers Squibb announces acquisition, collaboration
By Kelsey Kaustinen, DDNews Senior Editor
The company will acquire Flexus Biosciences for $1.25 billion, and will work with Rigel Pharmaceuticals to develop cancer immunotherapies
Facebook Facebook
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600 | Fax: 440-331-7563
©2015 Old River Publications LLC. All Rights Reserved.
Web site designed and managed by Offenberger & White, Inc..
If you no longer wish to receive DDNews mailings, please unsubscribe here.